QOP
RCKT icon

Quinn Opportunity Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Quinn Opportunity Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$245K – 383
2025
Q2 		$245K Buy
+100,000
New +$507K 0.02% 289

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Quinn Opportunity Partners's RCKT Position: Q3 2025 in Review

Quinn Opportunity Partners sold out of Rocket Pharmaceuticals (RCKT) in Q3 2025, closing a stake of 100,000 shares — an estimated $245K sold.

Quinn Opportunity Partners first reported a position in RCKT in Q2 2025 and held it in 1 quarter. The position peaked at $245K in Q2 2025. 173 funds tracked by Wall St. Rank hold RCKT as of Q3 2025.

  • Quinn Opportunity Partners reported no remaining Rocket Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Quinn Opportunity Partners sold 100,000 Rocket Pharmaceuticals shares in Q3 2025, an estimated $245K.
  • Quinn Opportunity Partners first reported a position in Rocket Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Quinn Opportunity Partners's Rocket Pharmaceuticals position peaked at $245K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2025.

Based on Quinn Opportunity Partners's 13F filing for Q3 2025, filed 13 Nov 2025.